Catalog No.
Product Name
Application
Product Information
Citations
-
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C8-NH2 is a synthesized E3 ligase ligand-linker conjugate that targets cereblon through its Thalidomide-derived component. This compound is designed for applications in PROTAC technology, facilitating targeted protein degradation. Its structure combines a specific ligand with a functional linker, making it a valuable tool for research in cellular signaling and protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG8-Ts is a synthesized E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with an eight-unit polyethylene glycol (PEG) linker. This compound is essential in the development of PROTAC (Proteolysis Targeting Chimeras) technology, enabling targeted degradation of specific proteins through the recruitment of E3 ligases. Its applications include research in targeted protein degradation, with potential implications in various therapeutic areas, including cancer and neurodegenerative diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-PEG4-amine TFA is an E3 ligase ligand-linker conjugate that combines a Thalidomide-derived cereblon ligand with a PEG4 linker for use in proteolysis-targeting chimera (PROTAC) applications. This compound facilitates targeted protein degradation by promoting the interaction between E3 ligases and specific substrate proteins. It serves as a valuable tool for researchers investigating cellular protein regulation and therapeutic interventions in various disease models. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed to incorporate a thalidomide-based cereblon ligand with a polyethylene glycol (PEG) linker. This compound facilitates targeted protein degradation through PROTAC technology, enhancing specificity and efficacy in research applications. It serves as a valuable tool for studying the role of E3 ligases in cellular processes and for developing novel therapeutic strategies through targeted modulation of protein levels. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand. This reagent plays a crucial role in PROTAC (proteolysis-targeting chimeras) technology, facilitating targeted protein degradation. It is of significant interest in drug discovery and development research, particularly for studies aimed at modulating protein function and enhancing therapeutic efficacy. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-O-C4-NH2 is an E3 ligase ligand-linker conjugate featuring a cereblon ligand derived from thalidomide, combined with a linker utilized in PROTAC technology. This compound is designed to selectively recruit E3 ligases for targeted protein degradation, making it valuable for studies in targeted therapy and drug development. It facilitates the exploration of protein dynamics and functions, contributing to advancements in cancer research and other diseases linked to protein misregulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand. This compound is designed to facilitate targeted protein degradation through PROTAC technology, enabling researchers to study protein interactions and dysregulation in various biological contexts. Its unique structure supports the development of novel therapeutic strategies by harnessing the ubiquitin-proteasome system for selective protein modulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C5-NH2 is an E3 ligase ligand-linker conjugate that utilizes the cereblon ligand derived from Thalidomide, combined with a linker suitable for targeted protein degradation applications. This compound facilitates the design of PROTAC molecules, enabling the selective degradation of target proteins via the ubiquitin-proteasome pathway. Its function in research may enhance studies related to therapeutic modalities in cancer and other diseases through targeted protein regulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C4-NH2 is a synthesized E3 ligase ligand-linker conjugate that targets cereblon, an E3 ubiquitin ligase. This compound is designed for use in PROTAC technology, enabling targeted protein degradation and facilitating the selective modulation of protein levels in cellular systems. It is suitable for research applications focused on protein homeostasis and therapeutic development for various diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C3-NH2 is an E3 ligase ligand-linker conjugate that integrates a thalidomide-derived cereblon ligand with a flexible linker designed for use in PROTAC (proteolysis-targeting chimera) technology. This compound facilitates the targeted ubiquitination and subsequent degradation of specific proteins, thereby allowing researchers to investigate protein function and regulation. Its applications extend to drug discovery and development, particularly in therapies targeting diseases driven by protein misfolding or dysregulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-NH-PEG1-NH2 TFA is an E3 ligase ligand-linker conjugate that targets Cereblon (CRBN). This compound serves as a critical ligand to recruit the CRBN protein, facilitating the development of proteolysis-targeting chimeras (PROTACs). It plays a significant role in studies focused on targeted protein degradation and E3 ligase modulation in biochemical and pharmacological research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C7-acid is a synthesized E3 ligase ligand-linker conjugate that utilizes the cereblon ligand derived from Thalidomide. This compound serves as a vital component in the development of PROTAC (proteolysis-targeting chimeras) technology, enabling targeted protein degradation. Thalidomide-O-C7-acid is instrumental for researchers focusing on protein regulation and therapeutic applications in various disease models. -
E3 Ligase Ligand-Linker Conjugate
Deoxy-thalidomide-Pip-C-PIP-boc is a conjugate that functions as an E3 ligase ligand-linker complex, featuring Thalidomide as a critical component. This compound acts as a Cereblon ligand, facilitating the recruitment of the CRBN protein, which is essential for targeted protein degradation. It serves as a vital intermediate in the synthesis of complete PROTAC (Proteolysis Targeting Chimeras) molecules, making it valuable for research in targeted therapeutic strategies and protein homeostasis. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PIP-(R)C-pyrrolidine-boc is a conjugate that acts as an E3 ligase ligand-linker complex, incorporating Thalidomide as the enabling component. This compound functions as a Cereblon ligand, facilitating the recruitment of the CRBN protein and serving as a crucial intermediate in the synthesis of PROTAC molecules. Its role in targeted protein degradation makes it a valuable tool for addressing complex biological questions in chemical biology and therapeutic development. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-amido-C5-NH2 is an E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand, designed for applications in PROTAC (Proteolysis Targeting Chimeras) technology. This compound facilitates targeted protein degradation, enabling researchers to investigate proteostasis and elucidate cellular mechanisms. Its use in drug discovery can enhance the development of novel therapeutics by modulating protein levels and activity in complex biological systems. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-PEG2-C2-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and 2-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C6-NH2 TFA (Cereblon Ligand-Linker Conjugates 11 TFA) is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG3-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 3-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG2-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 2-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
(S,R,S)-AHPC-PEG4-NH2 is a synthesized E3 ligase ligand-linker conjugate that incorporates the (S,R,S)-AHPC based VHL ligand and 4-unit PEG linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
cIAP1 Ligand-Linker Conjugates 11 Hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 11 Hydrochloride can be used to design SNIPERs. -
E3 ligase ligand-linker conjugate
cIAP1 Ligand-Linker Conjugates 15 hydrochloride incorporates an IAP ligand for the E3 ubiquitin ligase, and a PROTAC linker. cIAP1 Ligand-Linker Conjugates 15 hydrochloride can be used to design SNIPERs. -
E3 ligase ligand-linker conjugate
Pomalidomide-C2-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate that incorporates the Pomalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C3-NH2 TFA is a synthesized E3 ligase ligand-linker conjugate that incorporates the Thalidomide based cereblon ligand and a linker used in PROTAC technology. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG1-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that combines a thalidomide-based cereblon ligand with a polyethylene glycol (PEG) linker, designed for applications in PROTAC (proteolysis-targeting chimeras) technology. This reagent facilitates the targeted degradation of specified proteins, providing a valuable tool for researchers studying protein homeostasis and therapeutic intervention. Its unique properties make it suitable for various applications in chemical biology, drug discovery, and targeted protein degradation studies. -
E3 ligase ligand-linker conjugate
Thalidomide-O-amido-C3-COOH is an E3 ligase ligand-linker conjugate featuring a Thalidomide-based cereblon ligand. This compound is designed for use in PROTAC (Proteolysis Targeting Chimeras) technology, enabling targeted protein degradation. Its application is critical in studying the modulation of protein levels in various biological contexts, providing valuable insights into cellular pathways and disease mechanisms. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-C6-NH2 hydrochloride is an E3 ligase ligand-linker conjugate designed to incorporate the cereblon ligand derived from Thalidomide, along with a flexible linker suitable for PROTAC technology. This compound facilitates targeted protein degradation by linking specific binders to E3 ligases, enabling the modulation of protein expression in cellular studies. Its applications extend to research in drug discovery and the development of innovative therapeutic strategies involving targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugates E3
Thalidomide-O-C6-azide is an E3 ligase ligand-linker conjugate that combines the Thalidomide-based cereblon ligand with a versatile linker utilized in PROTAC technology. This compound features an azide functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) with alkyne-containing molecules, as well as strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with DBCO or BCN groups. Thalidomide-O-C6-azide is valuable for applications in targeted protein degradation and chemical biology studies. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C6-NH-Boc is an E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand, designed for use in PROTAC (proteolysis-targeting chimera) applications. This compound serves as a crucial building block for synthesizing MI-389, a potent phthalimide-based degrader derived from the multi-targeted receptor tyrosine kinase inhibitor sunitinib. Thalidomide-NH-C6-NH-Boc enables targeted protein degradation, facilitating research into protein regulation and therapeutic discovery in oncology and other fields. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide 4'-oxyacetamide-alkyl-C2-amine hydrochloride functions as an E3 ligase ligand-linker conjugate with high affinity for cereblon (CRBN). This compound is pivotal in the development of Proteolysis Targeting Chimeras (PROTACs), offering a strategic approach to induce targeted protein degradation. Its utility extends to research applications in cellular signaling pathways and therapeutic target validation, enabling the exploration of novel treatment modalities in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Piperazine-PEG1-NH2 is an E3 ligase ligand-linker conjugate that leverages the Thalidomide-derived cereblon ligand, facilitating targeted protein degradation through the PROTAC technology framework. This compound is designed for use in research applications aimed at elucidating E3 ligase biology and developing innovative therapeutic strategies. Its unique structure promotes effective interactions with cellular proteins, enhancing the specificity and efficiency of targeted degradation approaches. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-C6-NH2 TFA is an E3 ligase ligand-linker conjugate that combines the cereblon ligand derived from thalidomide with a hexylamine linker. This compound is designed for use in PROTAC technology, facilitating targeted protein degradation. It demonstrates significant potential in biochemical research, particularly in drug discovery and development focused on modulating protein levels through E3 ligase recruitment. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-NH-PEG2-C2-NH-Boc is an E3 ligase ligand-linker conjugate that features a thalidomide-based cereblon ligand combined with a polyethylene glycol (PEG) linker. This compound is designed for the synthesis of dBRD9, a selective PROTAC degrader that targets BRD9, facilitating investigations into BAF complex biology. It serves as a valuable tool in research applications focused on targeted protein degradation and the modulation of cellular pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG4-NH2 hydrochloride is a synthesized E3 ligase ligand-linker conjugate featuring a Thalidomide-based cereblon ligand. This compound is designed for use in PROTAC technology, facilitating targeted protein degradation. Its unique structure allows for the recruitment of E3 ligases, making it valuable in studies related to cellular processes and therapeutic development for various diseases. -
E3 Ligase Ligand-linker Conjugate
Thalidomide-PEG2-C2-NH2 TFA is an E3 ligase ligand-linker conjugate that combines the Thalidomide-derived cereblon ligand with a two-unit polyethylene glycol (PEG) linker. This compound is designed for use in the PROTAC (Proteolysis Targeting Chimera) technology, facilitating targeted protein degradation by promoting interactions with E3 ligases. It is applicable in research focused on cellular protein regulation and therapeutic development in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-C3-PEG3-C1-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-based cereblon ligand with a three-unit PEG linker. This compound facilitates targeted protein degradation through PROTAC (Proteolysis Targeting Chimera) technology, enhancing the specificity and efficacy of the therapeutic approach. It is suitable for research applications in the areas of protein modulation and drug discovery. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG2-C2-NH2 hydrochloride is a conjugate that targets E3 ligases, featuring a specific ligand and a flexible linker. This compound exhibits immunomodulatory properties and is utilized in cancer research, aiding investigations into targeted protein degradation and therapeutic strategies. Its unique structure facilitates the study of E3 ligase interactions, making it a valuable tool in oncology and drug development research. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-Piperazine-PEG2-NH2 is an E3 ligase ligand-linker conjugate that combines a thalidomide-derived cereblon ligand with a PEG2 linker, facilitating targeted protein degradation through the PROTAC technology. This compound is designed to enhance the specificity and efficacy of protein recruitment to the E3 ligase, making it a valuable tool for investigating the mechanisms of targeted ubiquitination and therapeutic intervention in various diseases. Its applications extend to drug discovery, particularly in the development of innovative treatments for conditions reliant on protein homeostasis. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG1-(C1-PEG)2-C2-NH2 TFA is an engineered E3 ligase ligand-linker conjugate that features a Thalidomide-based cereblon ligand combined with a three-unit PEG linker suitable for PROTAC technology. This compound facilitates targeted protein degradation through selective E3 ligase recruitment, making it valuable for studies in cellular biology and therapeutic applications. Its unique structure enhances solubility and stability in biological systems, promoting efficient conjugation in research endeavors. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-NH-PEG3-COOH is an E3 ligase ligand-linker conjugate that features a thalidomide-derived cereblon ligand combined with a PEG3 linker. This compound facilitates the targeted ubiquitination of specific proteins through PROTAC technology, promoting their degradation. It serves as a valuable tool for studies involving protein regulation and the development of targeted protein degradation strategies in cellular and molecular biology research. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Propargyne-PEG1-COOH is an E3 ligase ligand-linker conjugate that features a Thalidomide-based cereblon ligand, designed for use in PROTAC (Proteolysis Targeting Chimeras) applications. This compound is a versatile click chemistry reagent, possessing an alkyne moiety that facilitates copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its unique structure enables targeted protein degradation, making it a valuable tool for research in cellular signaling and therapeutics. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Propargyne-PEG3-COOH is an E3 ligase ligand-linker conjugate featuring a Thalidomide-derived cereblon ligand combined with a PEG3 linker, designed for use in PROTAC technology. This compound functions as a click chemistry reagent, possessing an alkyne group that enables copper-catalyzed azide-alkyne cycloaddition (CuAAc) with azide-containing molecules. Its applications in targeted protein degradation research make it a valuable tool for exploring protein regulation and therapeutic interventions. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-PEG3-COOH is an E3 ligase ligand-linker conjugate that combines the thalidomide-derived cereblon ligand with a PEG3 linker. This compound is designed for use in PROTAC (proteolysis-targeting chimera) technology, enabling targeted protein degradation. Its mechanism allows for selective modulation of protein levels, making it valuable in drug discovery and therapeutic research focused on protein homeostasis and regulation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-amido-PEG3-C2-NH2 hydrochloride serves as a synthesized E3 ligase ligand-linker conjugate, featuring a cereblon ligand derived from Thalidomide and a three-unit polyethylene glycol (PEG) linker. This compound is essential for the development of proteolysis-targeting chimeras (PROTACs), enabling targeted degradation of specific proteins in cellular research. Its unique structure facilitates effective interactions with E3 ligases, making it a valuable tool for studying protein regulation and potential therapeutic applications in cancer and other diseases. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG3-COOH is a synthesized E3 ligase ligand-linker conjugate, featuring a Thalidomide-based cereblon ligand connected by a PEG3 linker. This compound is designed to facilitate targeted protein degradation via PROTAC (Proteolysis Targeting Chimera) technology. Its biological activity makes it suitable for applications in protein regulation studies and drug discovery research, particularly in exploring E3 ligase-mediated pathways. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-O-C5-acid is a synthesized E3 ligase ligand-linker conjugate designed to engage cereblon, a key target in the ubiquitin-proteasome system. This compound serves as a crucial component in PROTAC technology, facilitating targeted protein degradation. Its utility in research includes the development of novel therapeutic strategies aimed at modulating protein levels in various biological contexts. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-Piperazine-PEG2-COOH is a synthesized E3 ligase ligand-linker conjugate designed to target cereblon. This compound utilizes a Thalidomide-based ligand and incorporates a PEG2 linker, facilitating the development of PROTAC (Proteolysis Targeting Chimera) technology. It is primarily used in chemical biology research to modulate protein levels through targeted degradation, making it valuable for investigations in cancer and other diseases where protein regulation is essential. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-4-O-C8-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate featuring the cereblon ligand derived from thalidomide, combined with a C8 linker. This compound is designed for use in PROTAC technology, facilitating the targeted degradation of proteins via the ubiquitin-proteasome pathway. Its application in chemical biology includes studies of protein modulation and therapeutic strategies in oncology and other disease models, enabling researchers to explore novel approaches in targeted protein degradation. -
E3 Ligase Ligand-Linker Conjugates
Thalidomide-PEG5-NH2 hydrochloride is an E3 ligase ligand-linker conjugate featuring the Thalidomide-derived cereblon ligand. This compound is designed to facilitate targeted protein degradation through PROTAC technology, enhancing cellular activity against specific protein targets. Its unique structure supports applications in drug development and research focused on modulating protein levels in various biological systems. -
E3 Ligase Ligand-Linker Conjugate
Thalidomide-PEG2-NH2 hydrochloride is an E3 ligase ligand-linker conjugate that integrates the Thalidomide-derived cereblon ligand with a polyethylene glycol (PEG) linker, designed for use in PROTAC (Proteolysis Targeting Chimera) technology. This compound facilitates targeted degradation of specific proteins via the ubiquitin-proteasome pathway, making it a valuable tool for research in targeted protein modulation. Its application extends to studies in cancer biology and therapeutic development, where selective protein degradation is crucial.
